New regional update
On 30 October 2026, the WHO South-East Asia regional news listing announced collaboration between WHO, CEPI and PATH to develop a standardized Nipah disease severity score. The stated objective is to strengthen outbreak preparedness and vaccine research.
Why severity definitions matter
Consistent descriptions of disease severity can help researchers compare patients across sites, interpret clinical outcomes and evaluate candidate interventions. A proposed score should be validated before it is used for clinical triage or treatment decisions.
Nipah: clinical and public-health context
Nipah virus infection can involve fever, neurological illness and respiratory manifestations. Suspected cases require prompt infection prevention measures, notification according to local public-health rules, and specialist assessment. Clinical manifestations alone cannot confirm infection; laboratory testing and public-health case definitions are essential.
Implications for hospitals
- Maintain appropriate recognition, isolation and referral procedures for suspected high-consequence infections.
- Use current national and state surveillance guidance for reporting and specimen handling.
- Do not substitute a research severity score for validated clinical protocols.
- Support standardized documentation of onset, symptoms, organ involvement and outcomes where authorized.
What remains uncertain
The announcement does not establish a finalized, validated scoring tool or a new approved Nipah treatment or vaccine. No scoring cutoffs or treatment doses are presented here.
Illustrative featured image: National Cancer Institute / Unsplash; not a Nipah virus image.
Official source
WHO South-East Asia regional news listing, 30 October 2026.